We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Shin Poong Pharmaceutical has reported that its antimalarial drug, Pyramax, failed to demonstrate statistical significance for the treatment of Covid-19 in the overall population in a Phase II study.